Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 1;7(11):1714-1716.
doi: 10.1001/jamaoncol.2021.4381.

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Thomas A Ollila  1   2 , Shaolei Lu  1   3 , Rebecca Masel  1 , Adam Zayac  1   2 , Kimberly Paiva  3 , Ralph D Rogers  1   4 , Adam J Olszewski  1   2
Affiliations

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Thomas A Ollila et al. JAMA Oncol. .

Abstract

This retrospective case series study examines immune response of adults with hematologic malignant disease who were vaccinated with 1 of 3 FDA-authorized COVID-19 vaccines between February and April of 2021.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Olszewski reported research funding from Genentech, TG Therapeutics, Celldex Pharmaceuticals, and Precision Bio; grants from Acrotech Pharma, Adaptive Biotechnologies outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Proportion of Vaccinated Patients With Hematologic Cancers Who Attain Postvaccination Seroconversion on the Qualitative IgG/IgM Assay
A, Prior monoclonal antibody exposure. B, Active disease, remission, or watchful waiting (WW) status at the time of vaccination; error bars indicate exact binomial 95% CIs.
See this image and copyright information in PMC

References

    1. Baden LR, El Sahly HM, Essink B, et al. ; COVE Study Group . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Ribas A, Sengupta R, Locke T, et al. ; AACR COVID-19 and Cancer Task Force . Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2021;11(2):233-236. doi:10.1158/2159-8290.CD-20-1817 - DOI - PMC - PubMed
    1. Paiva KJ, Grisson RD, Chan PA, et al. . Validation and performance comparison of three SARS-CoV-2 antibody assays. J Med Virol. 2021;93(2):916-923. doi:10.1002/jmv.26341 - DOI - PubMed
    1. Stephenson KE, Le Gars M, Sadoff J, et al. . Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021;325(15):1535-1544. doi:10.1001/jama.2021.3645 - DOI - PMC - PubMed

Substances